Macelignan attenuates LPS-induced inflammation and reduces LPS-induced spatial learning impairments in rats

Neuroscience Letters

Volumn 448, Issue 1, 2008, Pages 110-114

  Cui, Chun Ai ^a   Jin, Da Qing ^b   Hwang, Yoo Kyeong ^d   Lee, Im Soon ^d   Hwang, Jae Kwan ^c   Ha, Ilho ^b   Han, Jung Soo ^d  

^a YANBIAN UNIVERSITY   (China)

^b Inje University   (South Korea)

^c Yonsei University   (South Korea)

^d Konkuk University   (South Korea)

Author keywords

Alzheimer's disease; Macelignan; Memory; Microglia; Neuroinflammation

Indexed keywords

HERBACEOUS AGENT; LIPOPOLYSACCHARIDE; MACELIGNAN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BRAIN FOURTH VENTRICLE; CELL ACTIVATION; CEREBROSPINAL FLUID; COMPARATIVE STUDY; CONTROLLED STUDY; HIPPOCAMPUS; INFLAMMATION; LEARNING; LEARNING DISORDER; MALE; MAZE TEST; MEMORY DISORDER; MICROGLIA; NONHUMAN; PRIORITY JOURNAL; RAT; TASK PERFORMANCE;

ANALYSIS OF VARIANCE; ANIMALS; AVOIDANCE LEARNING; BEHAVIOR, ANIMAL; HISTOCOMPATIBILITY ANTIGENS CLASS II; INFLAMMATION; LEARNING DISORDERS; LIGNANS; LIPOPOLYSACCHARIDES; MALE; MAZE LEARNING; MICROGLIA; RATS; RATS, INBRED F344; REACTION TIME; SPACE PERCEPTION;

EID: 55549125155     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2008.10.035     Document Type: Article

References (29)

1. Gallagher M., Burwell R., and Burchinal M. Severity of spatial learning impairment in aging: development of a learning index for performance in the Morris water maze. Behav. Neurosci. 107 (1993) 618-626
2. Graupera M., Garcia-Pagan J.C., Abraldes J.G., Peralta C., Bragulat M., Corominola H., Bosch J., and Rodes J. Cyclooxygenase-derived products modulate the increased intrahepatic resistance of cirrhotic rat livers. Hepatology 37 (2003) 172-181
3. Haddad J.J. Mitogen-activated protein kinases and the evolution of Alzheimer's: a revolutionary neurogenetic axis for therapeutic intervention?. Prog. Neurobiol. 73 (2004) 359-377
4. Han K.L., Choi J.S., Lee J.Y., Song J., Joe M.K., Jung M.H., and Hwang J.K. Therapeutic potential of PPAR-{alpha}/{gamma} dual agonist with alleviation of ER stress for the treatment of diabetes mellitus. Diabetes (2007)
5. Hauss-Wegrzyniak B., Dobrzanski P., Stoehr J.D., and Wenk G.L. Chronic neuroinflammation in rats reproduces components of the neurobiology of Alzheimer's disease. Brain Res. 780 (1998) 294-303
6. Hauss-Wegrzyniak B., Lynch M.A., Vraniak P.D., and Wenk G.L. Chronic brain inflammation results in cell loss in the entorhinal cortex and impaired LTP in perforant path-granule cell synapses. Exp. Neurol. 176 (2002) 336-341
7. Hauss-Wegrzyniak B., Vannucchi M.G., and Wenk G.L. Behavioral and ultrastructural changes induced by chronic neuroinflammation in young rats. Brain Res. 859 (2000) 157-166
8. Hauss-Wegrzyniak B., Vraniak P., and Wenk G.L. The effects of a novel NSAID on chronic neuroinflammation are age dependent. Neurobiol. Aging 20 (1999) 305-313
9. Heneka M.T., Landreth G.E., and Hull M. Drug insight: effects mediated by peroxisome proliferator-activated receptor-gamma in CNS disorders. Nat. Clin. Pract. Neurol. 3 (2007) 496-504
10. Jin D.Q., Lim C.S., Hwang J.K., Ha I., and Han J.S. Anti-oxidant and anti-inflammatory activities of macelignan in murine hippocampal cell line and primary culture of rat microglial cells. Biochem. Biophys. Res. Commun. 331 (2005) 1264-1269
11. Jin D.Q., Sung J.Y., Hwang Y.K., Kwon K.J., Han S.H., Min S.S., and Han J.S. Dexibuprofen (S(+)-isomer ibuprofen) reduces microglial activation and impairments of spatial working memory induced by chronic lipopolysaccharide infusion. Pharmacol. Biochem. Behav. 89 (2008) 404-411
12. Jin M.J., Seo K., Ha I., and Han H.K. Determination of macelignan in rat plasma by high-performance liquid chromatography with ultraviolet detection. Arch. Pharm. Res. 31 (2008) 945-949
13. Kelloff G.J., Crowell J.A., Steele V.E., Lubet R.A., Malone W.A., Boone C.W., Kopelovich L., Hawk E.T., Lieberman R., Lawrence J.A., Ali I., Viner J.L., and Sigman C.C. Progress in cancer chemoprevention: development of diet-derived chemopreventive agents. J. Nutr. 130 (2000) 467S-471S
14. Kim D.S., Park S.Y., and Kim J.K. Curcuminoids from Curcuma longa L. (Zingiberaceae) that protect PC12 rat pheochromocytoma and normal human umbilical vein endothelial cells from betaA(1-42) insult. Neurosci. Lett. 303 (2001) 57-61
15. Lim G.P., Chu T., Yang F., Beech W., Frautschy S.A., and Cole G.M. The curry spice curcumin reduces oxidative damage and amyloid pathology in an Alzheimer transgenic mouse. J. Neurosci. 21 (2001) 8370-8377
16. Lim G.P., Yang F., Chu T., Chen P., Beech W., Teter B., Tran T., Ubeda O., Ashe K.H., Frautschy S.A., and Cole G.M. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease. J. Neurosci. 20 (2000) 5709-5714
17. McGeer E.G., and McGeer P.L. Inflammatory processes in Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 27 (2003) 741-749
18. Ono K., Hasegawa K., Naiki H., and Yamada M. Curcumin has potent anti-amyloidogenic effects for Alzheimer's beta-amyloid fibrils in vitro. J. Neurosci. Res. 75 (2004) 742-750
19. Pan M.H., Lin-Shiau S.Y., and Lin J.K. Comparative studies on the suppression of nitric oxide synthase by curcumin and its hydrogenated metabolites through down-regulation of IkappaB kinase and NFkappaB activation in macrophages. Biochem. Pharmacol. 60 (2000) 1665-1676
20. Ringman J.M., Frautschy S.A., Cole G.M., Masterman D.L., and Cummings J.L. A potential role of the curry spice curcumin in Alzheimer's disease. Curr. Alzheimer Res. 2 (2005) 131-136
21. Rosi S., Ramirez-Amaya V., Hauss-Wegrzyniak B., and Wenk G.L. Chronic brain inflammation leads to a decline in hippocampal NMDA-R1 receptors. J. Neuroinflamm. 1 (2004) 12
22. Sadhu S.K., Okuyama E., Fujimoto H., and Ishibashi M. Separation of Leucas aspera, a medicinal plant of Bangladesh, guided by prostaglandin inhibitory and antioxidant activities. Chem. Pharm. Bull. (Tokyo) 51 (2003) 595-598
23. Sohn J.H., Han K.L., Choo J.H., and Hwang J.K. Macelignan protects HepG2 cells against tert-butylhydroperoxide-induced oxidative damage. Biofactors 29 (2007) 1-10
24. Sohn J.H., Han K.L., Kim J.H., Rukayadi Y., and Hwang J.K. Protective effects of macelignan on cisplatin-induced hepatotoxicity is associated with JNK activation. Biol. Pharm. Bull. 31 (2008) 273-277
25. Stichtenoth D.O., and Frolich J.C. COX-2 and the kidneys. Curr. Pharm. Des. 6 (2000) 1737-1753
26. Tabet N., and Feldmand H. Ibuprofen for Alzheimer's disease. Cochrane Database Syst. Rev. (2003) CD004031
27. Warner T.D., Giuliano F., Vojnovic I., Bukasa A., Mitchell J.A., and Vane J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U.S.A. 96 (1999) 7563-7568
28. Wenk G.L. Neuropathologic changes in Alzheimer's disease. J. Clin. Psychiatry 64 Suppl. 9 (2003) 7-10
29. Woo W., Shin K., Wagner H., and Lotter H. The structure of macelignan from Myristica fragrans. Phytochemistry 26 (1987) 1542-1543